Aura Biosciences(AURA) - 2025 Q1 - Quarterly Results

Financial Performance - Aura Biosciences reported a net loss of $27.5 million for Q1 2025, compared to a net loss of$ 19.7 million for Q1 2024, reflecting an increase of approximately 39% year-over-year [21]. - The comprehensive loss for Q1 2025 was $27.6 million, compared to$ 20.2 million in Q1 2024 [24]. - General and administrative expenses increased to $5.7 million in Q1 2025 from$ 5.3 million in Q1 2024, driven by higher personnel costs [21]. Research and Development - Research and development expenses rose to $23.3 million in Q1 2025 from$ 17.1 million in Q1 2024, primarily due to ongoing clinical trial costs [17]. - The ongoing Phase 1b/2 trial for NMIBC will evaluate bel-sar in approximately 26 patients, with initial efficacy data expected by year-end 2025 [12]. - The CoMpass trial for early-stage choroidal melanoma has enrolled over 220 patients in a pre-screening tool since June 2024, with completion expected by the end of 2025 [4]. - The company expects initial data from the Phase 2 trial for metastases to the choroid in 2025, with a focus on a basket study approach [7]. - Bel-sar is being explored for three ocular oncology indications, collectively affecting over 60,000 patients annually in the U.S. and Europe [6]. - The company has filed a patent application for a new formulation of bel-sar for bladder cancer, aimed at enhancing in-office urologist procedures [10]. Financial Position - As of March 31, 2025, the company had cash and cash equivalents totaling $128.0 million, sufficient to fund operations into the second half of 2026 [17]. - Total assets decreased from$ 182,503 million as of December 31, 2024, to $155,401 million as of March 31, 2025, representing a decline of approximately 14.85% [26]. - Total current assets decreased from$ 160,623 million to $134,517 million, a reduction of about 16.26% [26]. - Stockholders' equity decreased from$ 151,970 million to $127,966 million, reflecting a decline of approximately 15.77% [26]. - Cash and cash equivalents increased from$ 31,693 million to $38,226 million, an increase of about 20.04% [26]. - Total liabilities decreased from$ 30,533 million to $27,435 million, a decrease of approximately 10.14% [26]. - Total current liabilities decreased from$ 14,913 million to $12,163 million, a decrease of about 18.43% [26]. - Long-term operating lease liability slightly decreased from$ 15,620 million to $15,272 million, a reduction of about 2.23% [26]. - Additional paid-in capital increased from$ 525,934 million to $529,571 million, a growth of about 0.25% [26]. - Accumulated deficit increased from$ (374,227) million to $(401,710) million, indicating a worsening of approximately 7.36% [26]. - Accumulated other comprehensive income decreased from$ 263 million to $105 million, a decline of approximately 60.00% [26].